Glycogen storage disease 1a
Glycogen storage disease 1a-13562
3/20/2023: This test order is currently unavailable. To order a referred alternate, place a MSO order for LabCorp (482370) GeneSeq PLUS
von Gierke disease
Glycogen storage disease type 1a (GSD1a), also called von Gierke disease (OMIM 232200), is a recessive inherited disorder characterized by an enlarged liver and kidneys due to the accumulation of glycogen and fat
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times to prevent clotting
Lavender (EDTA), 10mL
Amniotic fluid
Chorionic villus sample/CVS (submission of maternal blood is required for fetal testing)
ACD whole blood
Yellow ACD (A or B)
Amniotic fluid or Chorionic villus sample (CVS)
Sterile vial/container
Amniotic fluid - 10mL (minimum 5mL)
Chorionic villus sample /CVS - 20 mg (minimum 10 mg)
Whole blood - Yellow ACD (A or B)
Amniotic fluid or Chorionic villus sample (CVS) - Sterile vial/container
Molecular Medicare billing request
Hospital clients submitting a reqeust for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request along with the sample
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed
Ambient
Refrigerated
- Frozen specimen
- Hemolysis
- Quantity not sufficient for analysis (QNS)
- Improper container
If cultured cells are needed, an additional 7 - 12 days may be required
Polymerase chain reaction (PCR) and primer extension
An interpretive report will be provided
Some infants who are untreated develop severe hypoglycemia ( low blood sugar). Long term complications of untreated GSD1a include short stature, osteoporosis, delayed puberty, kidney disease, liver disease, seizures, and mental retardation. This condition is caused by a deficiency of the enzyme D-glucose-6-phosphatase (G6Pase), and can be treated by making dietary changes and maintaining normal levels of glucose to prevent hypoglycemia. Individuals who are treated can be expected to have normal growth and many live intoadulthood. The disease has elevated prevalence among Ashkenazi Jews, with a carrier rate of 1 in 71, although it is seen in all ethnic goups. Carriers of GSD1a do not exhibit symptoms that would lead one to suspect their carrier status. When both parents are carriers of GSD1a, there is a 25% chance with each pregnancy to have a child with the disease. Prenatal diagnosis is available. Molecular genetic testing for GSD1a encompasses two mutations in the gene encoding D-glucose-6-phosphatase (G6Pase, OMIM 611045). Testing for these two mutations identifies 99% of GSD1a carriers that are Ashkenazi Jewish, and approximately 60% of GSD1a carriers that are non-Ashkenazi Jewish Caucasian. Biochemical analysis ofliver biopsy specimens can be performed for diagnostic purposes but does not determine carrier status. A negative test result decreases the likelihood that a person is a carrier, but cannot completely eliminate the possibility. The presence of a rare mutation cannot be ruled out. DNA test results must be combined with clinical information for the most accurate interpretation.
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed